{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:39:52Z","timestamp":1758271192670,"version":"3.37.3"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.vaccine.2024.126589","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T03:41:55Z","timestamp":1734925315000},"page":"126589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Impact on meningococcal disease of different vaccination strategies with 4CMenB and MenACWY-CRM197 in infants and adolescents in Argentina"],"prefix":"10.1016","volume":"45","author":[{"given":"Jorge Alberto","family":"G\u00f3mez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Eugenia","family":"Pannunzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Karwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florencia","family":"Nocita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Analia","family":"Urue\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norberto","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Gabriela","family":"Gra\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126589_bb0005","series-title":"Cane A Epidemiological burden of meningococcal disease in Latin America: A systematic literature review International journal of infectious diseases\u202f: IJID","first-page":"37","volume":"85","author":"Vespa Presa","year":"2019"},{"key":"10.1016\/j.vaccine.2024.126589_bb0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","article-title":"Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup b invasive meningococcal disease","volume":"24","author":"Beck","year":"2021","journal-title":"Value In Health\u202f:J of Int Soc Pharmacoeconom Outcomes Res"},{"key":"10.1016\/j.vaccine.2024.126589_bb0015","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1186\/s12889-022-13342-2","article-title":"Range of invasive meningococcal disease sequelae and health economic application - a systematic and clinical review","volume":"22","author":"Shen","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2024.126589_bb0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2024.126589_bb0025","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2237391","article-title":"Meningococcal burden of disease in Argentina: 10 years epidemiologic review","author":"Neyro","year":"2023","journal-title":"Hum Vaccin Immunother"},{"author":"World Health Organization (WHO)","key":"10.1016\/j.vaccine.2024.126589_bb0030"},{"key":"10.1016\/j.vaccine.2024.126589_bb0035","series-title":"Vaccines against Meningococcal Diseases Microorganisms","first-page":"1521","volume":"8","author":"Pizza","year":"2020"},{"key":"10.1016\/j.vaccine.2024.126589_bb0040","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1056\/NEJMoa2214924","article-title":"Meningococcal ACWYX conjugate vaccine in 2-to-29-year-olds in Mali and Gambia","volume":"388","author":"Haidara","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126589_bb0045","doi-asserted-by":"crossref","first-page":"e1661","DOI":"10.1093\/cid\/ciaa1244","article-title":"First real-world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease: prospective enhanced National Surveillance","volume":"73","author":"Ladhani","year":"2021","journal-title":"England Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126589_bb0055","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1016\/j.vaccine.2020.08.007","article-title":"Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England","volume":"38","author":"Beck","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126589_bb0060","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1080\/21645515.2021.1996808","article-title":"Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile","volume":"17","author":"Gra\u00f1a","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.126589_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009098","article-title":"Projecting contact matrices in 177 geographical regions: an update and comparison with empirical data for the COVID-19 era","volume":"17","author":"Prem","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.vaccine.2024.126589_bb0075","article-title":"Oropharyngeal meningococcal carriage in children and adolescents, a single center study in Buenos Aires","volume":"16","author":"Gentile","year":"2021","journal-title":"Argentina PLoS One"},{"key":"10.1016\/j.vaccine.2024.126589_bb0080","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"year":"2019","series-title":"Portuguese meningococcus group B vaccine effectiveness study (PT-BEST) - preliminary results","author":"Rodrigues","key":"10.1016\/j.vaccine.2024.126589_bb0090"},{"key":"10.1016\/j.vaccine.2024.126589_bb0095","first-page":"139","article-title":"Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine","author":"Cohn","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2024.126589_bb0100","first-page":"258","article-title":"Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: a randomised trial","volume":"76","author":"Martinon-Torres","year":"2018","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2024.126589_bb0105","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1097\/INF.0000000000000897","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2024.126589_bb0110","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.vaccine.2013.09.034","article-title":"Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model","volume":"33","author":"Vickers","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126589_bb0115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/21645515.2015.1058457","article-title":"Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine","volume":"12","author":"Vesikari","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.126589_bb0120","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/INF.0000000000000438","article-title":"Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents","volume":"33","author":"Baxter","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2024.126589_bb0125","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2024.126589_bb0130","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1016\/j.vaccine.2020.09.050","article-title":"Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates","volume":"38","author":"Biolchi","year":"2020","journal-title":"Vaccine"},{"year":"2019","series-title":"Abstract ESPID19\u20130255: A Multicomponent Meningococcal Serogroup B Vaccine Developed for Serogroup B Meningococci Elicits Cross-Reactive Immunity Against Serogroups C, W and Y","author":"Pizza","key":"10.1016\/j.vaccine.2024.126589_bb0135"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T15:12:37Z","timestamp":1739200357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24012714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":24,"alternative-id":["S0264410X24012714"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126589","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact on meningococcal disease of different vaccination strategies with 4CMenB and MenACWY-CRM197 in infants and adolescents in Argentina","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126589"}}